FDA Requires Safety Labeling Changes for Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RAs) Due to Potential Increased Risk of Rare But Serious Eye ConditionU.S. Food and Drug Administration (FDA), November 9, 2026Open on fda.gov
2
Risk of Nonarteritic Anterior Ischemic Optic Neuropathy in Patients Prescribed SemaglutideHathaway JT, et al. JAMA Ophthalmology, 2024Open on PubMed
3
Once-weekly semaglutide doubles the five-year risk of nonarteritic anterior ischemic optic neuropathy in a Danish cohort of 424,152 persons with type 2 diabetesGrauslund J, et al. International Journal of Retina and Vitreous, 2024Open on PubMed
4
Semaglutide and Nonarteritic Anterior Ischemic Optic NeuropathyCai CX, et al. JAMA Ophthalmology, 2025Open on PubMed
Updates and corrections
None so far. If newer evidence changes the answer, I'll note it here with the date.